Zoetis Inc. (NYSE:ZTS) Shares Sold by Sachetta LLC

Sachetta LLC cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 2.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,810 shares of the company’s stock after selling 53 shares during the quarter. Sachetta LLC’s holdings in Zoetis were worth $330,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Webster Bank N. A. raised its stake in shares of Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after buying an additional 82 shares in the last quarter. Private Wealth Management Group LLC acquired a new stake in Zoetis in the fourth quarter valued at $33,000. Neo Ivy Capital Management acquired a new stake in Zoetis in the fourth quarter valued at $40,000. LRI Investments LLC purchased a new stake in shares of Zoetis during the 1st quarter worth $43,000. Finally, Blue Bell Private Wealth Management LLC grew its stake in shares of Zoetis by 111.6% during the 1st quarter. Blue Bell Private Wealth Management LLC now owns 273 shares of the company’s stock worth $46,000 after purchasing an additional 144 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Piper Sandler boosted their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. BTIG Research raised their price target on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $200.00 price objective on shares of Zoetis in a research report on Tuesday, August 27th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $217.11.

Zoetis Trading Up 1.3 %

Zoetis stock opened at $191.73 on Tuesday. The stock has a market cap of $86.86 billion, a PE ratio of 36.94, a P/E/G ratio of 2.90 and a beta of 0.88. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The stock has a 50-day moving average price of $181.60 and a 200 day moving average price of $174.36. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The business had revenue of $2.36 billion during the quarter, compared to analyst estimates of $2.31 billion. During the same quarter in the previous year, the business posted $1.41 earnings per share. The company’s revenue was up 8.3% on a year-over-year basis. Equities research analysts predict that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.